N. Jones K. Flamm, H. S. Sader; JMI Lab., N Liberty, IA. C2-139 E. Ross, R. E. Mendes, R. K. Flamm, R. N. Jones; JMI Lab., N Liberty, IA. C2-140 Hawser

45 SUNDAY SCIENTIFIC SESSIONS Final Program ------------------------------------------------------------------------ 010 C2 Poster Session Multi-Center Surveillance Studies Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-123 Ceftaroline Activity Tested against Pathogens Associated With Acute Bacterial Skin and Skin Structure Infections ABSS- SI Isolated From Latin American Medical Centers 2010

D. J. Biedenbach, H. S. Sader, R. K. Flamm, R. N. Jones; JMI Lab., Inc., N Liberty, IA.

C2-124 Antimicrobial Activity of Ceftaroline and Comparator Agents Tested against Contemporary 2010 Pathogens Associ- ated with Acute Bacterial Skin and Skin Structure Infections ABSSSI Isolated from the Asia-Pacific Region APAC and South Africa SAF

P. R. Rhomberg, R. K. Flamm, R. N. Jones, H. S. Sader; JMI Lab., N Liberty, IA.

C2-125 Comparative In Vitro Activity of Sitafloxacin SIT Relative to Other Fluoroquinolones against Clinically Important Bacteria Isolated in Asia and Europe

J. Deane, A. Simenauer, D. Sahm; Eurofins, Chantilly, VA. C2-126

In Vitro Activity of Ceftaroline against Staphylococcus aureus SA from Consecutive U.S. Nationwide Surveillance Program 2009 and 2011 G. Doern 1 , S. Richter 2 , K. Heilmann 1 , C. Dohrn 1 , F. Riahi 1 , D. Diekema 1 ; 1 Univ. of Iowa, Iowa City, IA, 2 Cleveland Clinic, Cleveland, OH. C2-127 Comparative In Vitro Activity of Ceftaroline, Daptomycin, Linezolid, and Vancomycin against 512 Bacteremic Methicillin- Resistant Staphylococcus aureus Isolated Over a Period of 9 Years 2004-2012 in Madrid, Spain E. Cercenado, B. Gama, C. Sánchez-Carrillo, M. Marín, M. Rodríguez- Créixe, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain. C2-128 A Five Year Comparison of Vancomycin VAN and Orita- vancin ORI In Vitro Activities against Staphylococci

J. Deane

1 , A. Simenauer 1 , G. Moeck 2 , F. F. Arhin 2 , D. Sahm 1 ; 1 Eurofins, Chantilly, VA, 2 The Med. Company, Parsippany, NJ. C2-129 Antimicrobial Susceptibility of S. aureus from USA Hospitals According to the Site of Infection: Data from the Ceftaroline AWARE Surveillance Program 2008-2011

H. S. Sader, R. K. Flamm, R. N. Jones; JMI Lab., Inc., N Liberty, IA. C2-130

Activity of Ceftaroline Tested against Staphylococcus Collected from a Nationwide Study in Spain, 2010 E. Cercenado, B. Gama, O. Cuevas, M. Marín, E. Bouza, Staphylococcus Study Group; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain. C2-131 Ceftaroline and Comparator Agent Activity against Con- temporary 2010 Staphylococcus aureus Isolates from Asia-Pacific APAC Region and South Africa Hospitals

P. R. Rhomberg, R. K. Flamm, R. N. Jones, H. S. Sader; JMI Lab., Inc., N Liberty, IA.

C2-132 Oritavancin Activity Tested against Staphylococcus aureus and ơ-Hemolytic Streptococci Causing Skin and Skin Structure Infections in the USA 2010−2012 R. E. Mendes, H. S. Sader, R. K. Flamm, R. N. Jones; JMI Lab., N Liberty, IA. C2-133 Monitoring Cross-Resistance Trends Between Tigecycline and Minocycline in Gram-Positive Blood Isolates Test 2008 - 2011

S. Hawser

1 , C. Zampaloni 1 , F. Monti 1 , S. Bouchillon 2 ; 1 IHMA Europe Sàrl, Epalinges, Switzerland, 2 IHMA, Inc., Schaumburg, IL. C2-134 Comparative In Vitro Activity of Dalbavancin DAL and Other Gram-Positive Agents against a Recent Collection of European Bacterial Isolates

J. Deane

1 , A. Simenauer 1 , M. Dunne 2 , B. P. Goldstein 3 , D. Sahm 1 ; 1 Eurofins Medinet, Chantilly, VA, 2 Durata Therapeutics, Morristown, NJ, 3 None, Morristown, NJ. C2-135 Antimicrobial Susceptibility of 27,123 Pathogens Isolated from Patients in Canadian Hospitals: CANWARD Study 2007- 2011 G. G. Zhanel 1 , H. Adam 2 , M. Baxter 1 , K. Nichol 2 , A. Denisuik 1 , P. Lagace-Wiens 2 , A. Walkty 2 , J. A. Karlowsky 2 , F. Schweizer 1 , Cana- dian Antimicrobial Resistance Alliance-CARA, D. J. Hoban 2 ; 1 Univ. of Manitoba, Winnipeg, Canada, 2 Diagnostic Services of Manitoba, Winnipeg, Canada. C2-136 Emerging Markets Resistance Surveillance EMRS Program Report for Eastern European EEU Nations R. N. Jones, M. G. Stilwell, R. K. Flamm, H. S. Sader; JMI Lab., N Liberty, IA. C2-137 Nationwide Surveillance on the Antimicrobial Resistance among Blood Isolates Causing Bacteremia: A 2011 Korean Net- work for Study on Infectious Diseases KONSID Study K. Huh, S. Y. Park, S. Y. Cho, C. I. Kang, D. R. Chung, N. Y. Lee, K. R. Peck, J. H. Song, Korean Network for Study on Infectious Diseases KON- SID; Samsung Med. Ctr., Seoul, Korea, Republic of. C2-138 Update of Dalbavancin DAL Activity in the USA: Report from the SENTRY Program 2011 R. N. Jones R. K. Flamm, H. S. Sader; JMI Lab., N Liberty, IA. C2-139 Linezolid Experience and Accurate Determination of Resis- tance LEADER Program for 2011: USA Surveillance Report

J. E. Ross, R. E. Mendes, R. K. Flamm, R. N. Jones; JMI Lab., N Liberty, IA. C2-140

Trends in Activity of Tigecycline against Bacteroides spp. from Cardiovascular Sources TEST 2008 - 2011

S. Hawser

1 , C. Zampaloni 1 , F. Monti 1 , S. Bouchillon 2 ; 1 IHMA Europe Sàrl, Epalinges, Switzerland, 2 IHMA, Inc., Schaumburg, IL. C2-141 Comparison of Tigecycline Activity against Aerobic Intra- Abdominal Pathogens in Eastern and Western European Countries: TEST 2008-2011 S. Lob, S. Bouchillon, M. Hackel, D. Hoban, J. Johnson; IHMA, Inc., Schaumburg, IL.